Cargando…

Low-dose paroxetine (7.5 mg) improves sleep in women with vasomotor symptoms associated with menopause

OBJECTIVE: Sleep disturbances are common among women in midlife; prevalence increases among perimenopausal/postmenopausal women with vasomotor symptoms. Paroxetine 7.5 mg is the only nonhormonal treatment that has been approved in the United States for moderate to severe vasomotor symptoms associate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pinkerton, JoAnn V., Joffe, Hadine, Kazempour, Kazem, Mekonnen, Hana, Bhaskar, Sailaja, Lippman, Joel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott-Raven Publishers 2015
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4274337/ https://www.ncbi.nlm.nih.gov/pubmed/25137243 http://dx.doi.org/10.1097/GME.0000000000000311

Ejemplares similares

Effects of low-dose paroxetine 7.5 mg on weight and sexual function during treatment of vasomotor symptoms associated with menopause
por: Portman, David J., et al.
Publicado: (2014)

Neurokinin Receptor Antagonist, Fezolinetant, for Treatment of Menopausal Vasomotor Symptoms
por: Pinkerton, JoAnn V, et al.
Publicado: (2023)

Menopausal Vasomotor Symptoms and Risk of Incident Cardiovascular Disease Events in SWAN
por: Thurston, Rebecca C., et al.
Publicado: (2021)

Critical appraisal of paroxetine for the treatment of vasomotor symptoms
por: Carroll, Dana G, et al.
Publicado: (2015)

Premenstrual Disorders, Timing of Menopause, and Severity of Vasomotor Symptoms
por: Yang, Yihui, et al.
Publicado: (2023)

Vasomotor and physical menopausal symptoms are associated with sleep quality
por: Kim, Min-Ju, et al.
Publicado: (2018)

A Clinical Review on Paroxetine and Emerging Therapies for the Treatment of Vasomotor Symptoms
por: David, Paru S, et al.
Publicado: (2022)

Vasomotor symptoms in midlife women with incident breast cancer: pink SWAN
por: Gold, Ellen B., et al.
Publicado: (2021)

Magnitude of placebo response in clinical trials of paroxetine for vasomotor symptoms: a meta-analysis
por: Rhodes, Joshua R., et al.
Publicado: (2023)

Hops for Menopausal Vasomotor Symptoms: Mechanisms of Action
por: Abdi, Fatemeh, et al.
Publicado: (2016)

OR11-03 NT-814, a Non-Hormonal Dual Neurokinin 1,3 Receptor Antagonist Markedly Improves Vasomotor Symptoms in Post-Menopausal Women; Results of a Randomised, Double-Blind, Placebo-Controlled, Dose-Finding Study (SWITCH-1)
por: Simon, James, et al.
Publicado: (2020)

Association of menopausal vasomotor symptom severity with sleep and work impairments: a US survey
por: DePree, Barbara, et al.
Publicado: (2023)

Effects of NT-814, a dual neurokinin 1 and 3 receptor antagonist, on vasomotor symptoms in postmenopausal women: a placebo-controlled, randomized trial
por: Trower, Mike, et al.
Publicado: (2020)

Association of Menopausal Vasomotor Symptoms With Increased Bone Turnover During the Menopausal Transition
por: Crandall, Carolyn J, et al.
Publicado: (2011)

Treatment options for vasomotor symptoms in menopause: focus on desvenlafaxine
por: Umland, Elena M, et al.
Publicado: (2012)

Comparative study of gabapentin and isoflavone in menopausal vasomotor symptoms
por: Singhal, Savita Rani, et al.
Publicado: (2016)

Psychosomatic and vasomotor symptom changes during transition to menopause
por: Augoulea, Areti, et al.
Publicado: (2019)

MON-387 Pheochromocytoma Masquerading as Vasomotor Menopausal Symptoms
por: Xhikola, Majlinda, et al.
Publicado: (2019)

Vasomotor Symptoms: More Than Temporary Menopausal Symptoms
por: Ryu, Ki-Jin, et al.
Publicado: (2020)

Effects of oral versus transdermal menopausal hormone treatments on self-reported sleep domains and their association with vasomotor symptoms in recently menopausal women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS)
por: Cintron, Dahima, et al.
Publicado: (2018)

A dietary intervention for vasomotor symptoms of menopause: a randomized, controlled trial
por: Barnard, Neal D., et al.
Publicado: (2023)

Neurokinin 3 receptor antagonists for menopausal vasomotor symptoms, an appraisal
por: Gompel, Anne, et al.
Publicado: (2023)

Treatment Strategies for Reducing the Burden of Menopause-Associated Vasomotor Symptoms
por: Umland, Elena M.
Publicado: (2008)

Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: A comprehensive review
por: Utian, Wulf H
Publicado: (2005)

Investigation of the relationship between personality characteristics and vasomotor symptoms in menopausal women
por: Ghorbani, Mahboubeh, et al.
Publicado: (2016)

RANKL is a new Epigenetic Biomarker for the Vasomotor Symptom During Menopause
por: Kalkan, R, et al.
Publicado: (2020)

Compounded non-FDA–approved menopausal hormone therapy prescriptions have increased: results of a pharmacy survey
por: Pinkerton, JoAnn V., et al.
Publicado: (2016)

Comparative Efficacy of Zolpidem and Nigella Sativa in Treatment of Sleep Disorder and Vasomotor Symptoms in Menopausal Women of Women’s General Hospital
por: Asadi, Mojgan, et al.
Publicado: (2020)

Acupuncture for menopausal vasomotor symptoms: study protocol for a randomised controlled trial
por: Pirotta, Marie, et al.
Publicado: (2014)

Combined Red Clover isoflavones and probiotics potently reduce menopausal vasomotor symptoms
por: Lambert, Max Norman Tandrup, et al.
Publicado: (2017)

Variation in menopausal vasomotor symptoms outcomes in clinical trials: a systematic review
por: Iliodromiti, S, et al.
Publicado: (2019)

Safety of Fezolinetant for Vasomotor Symptoms Associated With Menopause: A Randomized Controlled Trial
por: Neal-Perry, Genevieve, et al.
Publicado: (2023)

Neurokinin receptor antagonists as potential non-hormonal treatments for vasomotor symptoms of menopause
por: Conklin, Melissa, et al.
Publicado: (2023)

“Veozah (Fezolinetant): A Promising Non‐Hormonal Treatment for Vasomotor Symptoms in Menopause”
por: Shaukat, Ayesha, et al.
Publicado: (2023)

Qualitative study: burden of menopause-associated vasomotor symptoms (VMS) and validation of PROMIS Sleep Disturbance and Sleep-Related Impairment measures for assessment of VMS impact on sleep
por: English, Marci, et al.
Publicado: (2021)

Effect of Lavender on Sleep, Sexual Desire, Vasomotor, Psychological and Physical Symptom among Menopausal and Elderly Women: A Systematic Review
por: Roozbeh, Nasibeh, et al.
Publicado: (2019)

Effect of Experimentally Induced Sleep Fragmentation and Hypoestrogenism on Fasting Nutrient Utilization in Pre-Menopausal Women
por: Grant, Leilah K, et al.
Publicado: (2021)

Correction to: Qualitative study: burden of menopause-associated vasomotor symptoms (VMS) and validation of PROMIS sleep disturbance and sleep-related impairment measures for assessment of VMS impact on sleep
por: English, Marci, et al.
Publicado: (2021)

Management of menopause-associated vasomotor symptoms: Current treatment options, challenges and future directions
por: Pachman, Deirdre R, et al.
Publicado: (2010)

Nonpharmacologic, nonherbal management of menopause-associated vasomotor symptoms: an umbrella systematic review (protocol)
por: Goldstein, Karen M., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_gcbneu30gn9lpral207essc1e8